Canada's AmorChem launches $44.2M life science fund; Neon adds $36M, Merck partnership in neoantigen drive; CRISPR Therapeutics files a CTA
→ Canadian VC firm AmorChem Group has raised $44.2 million for its second life science fund. Backed by LPs including the Québec government, Montreal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.